肥厚型梗阻性心肌病室间隔心肌消融术的国专家共识

肥厚型梗阻性心肌病室间隔心肌消融术的 国专家共识 中华医学会心血管病学分会 中华心血管病杂志编辑委员会 室间隔心肌消融术治疗专组 肥厚型梗阻性心肌病( hypertrophic obstructive cardiomyopathy，HOCM)是肥厚型心肌病的一种，因 肥厚室间隔造成心室梗阻而得名。目前尚无理想的 治疗措施，药物治疗为首选。但 部分HOCM患者药 物治疗效果不佳或不能耐受，这部分患者需要借助 非药物治疗方法。非药物治疗方法包括手术和介入 治疗，经皮穿刺腔内间隔心肌消融术（percutaneous transluminal septal myocardial ablation,PTSMA）是一 种介入治疗手段，其原理是通过导管注入无水酒精， 闭塞冠状动脉的间隔支，使其支配的肥厚室间隔心 肌缺血、坏死、变薄、收缩力下降，使心室流出道梗阻 消失或减轻，从而改善HOCM患者的临床症状[1]。 10. 3760/cma. j. issn. 0253-3758. 2011.10. 004 万方数据 其压差 万方数据 心包填塞 万方数据 静息 万方数据 @@[1]Kimmelstiel C,Krishnamurthy B，Weintraub A，等.酒精室间 隔消融术与肥厚型心肌病.中华心血管病杂志，2009，37: 1074-1077. @@[2] Waller BF, Maron BJ, Epstein SE, et al. Transmural myocardial infarction in hypertrophic cardiomyopathy: a cause of conversion from left ventricular asymmetry to symmetry and from normal-sized to dilated left ventricular cavity. Chest, 1981,79:461-465. @@[ 3 ] Sigwart U, Gribic M, Payor M, et al. Wall motion during balloon occlusion.//Sigwart U, Heintzen PH. Ventricular wall motion. Stuttgart : Georg Thieme, 1983:206-210. @@[4] Gietzen F,Leuner C,Gerenkamp T,et al. Relief of obstruction in hypertrophic cardiomyopathy by transient occlusion of the first septal branch of the left coronary artery. Eur Heart J, 1994,15 ( Suppl ) : 125-130. @@[5] Sigwart U. Non-surgical myocardial reduction for hypertropic obstructive cardiomyopathy. Lancet, 1995,346:211-214. @@[6]赵林阳，王大伟，杨平，等.经导管化学消蚀心肌治疗肥厚性梗 阻型心肌病（附一例）.中华心血管病杂志，1998，26:70- 71. @@[7]中华心血管病杂志编委会经皮经腔间隔心肌消融术治疗专题 组.经皮经腔间隔心肌消融术治疗的参考意见.中华心血管病 杂志，2001，29:434-435. @@ [ 8 ] Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal ablation in hypertropic obstructive cardiomyopathy. Thorac Cardiovasc Surg, 1999, 47:94-100. @@ [9] Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Interv Cardio1,2006 ,19 :319-327. @@[10] Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy . A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol, 2003,42 : 1687-1713. @@[ 11 ] Seggewiss H, Rigopoulos A, Welge D, et al. Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardio1,2007,96 : 851-855. @@[12] Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta analysis. Eur Heart J,2009,30: 1080-1087. @@[ 13 ] Agarwal S, Tuzcu EM, Desai MY, et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol, 2010,55:823-834. @@[ 14 ] Lyne JC, Kilpatrick T, Duncan A, et al. Long-term follow-up of the first patients to undergo transcatheter alcohol septal ablation. Cardiology,2010,116 : 168-173. @@[ 15 ] Leonardi RA, Kransdorf EP, Simel DL, et al. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv,2010,3:97- 104. @@[16]辽宁省化学消融术协作组.经皮经冠状动脉室间隔化学消融 万方数据 术治疗梗阻性肥厚型心肌病的近期疗效观察.中华心血管病 杂志，2001,29:8-11. @@[17]张明，李占全，金元哲，等.经皮经腔间隔心肌化学消融术治疗 肥厚型梗阻性心肌病两年疗效观察.中华心血管病杂志, 2003,31:122-125. @@[18] Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation ,2008,118 : 131-139. @@[ 19 ] Fernandes VL, Nielsen C, Nagueh SF, et al. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy, the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC,2008,1:561-570. @@[ 20 ] Kwon DH, Kapadia SR, Tuzcu M, et al. Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation. JACC, 2008,1:432-438. @@[21] Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy. Circulation ,2008,117:429-439. @@[22] Delling FN, Sanbom DY, Levine RA, et al. Frequency and mechanism of persistent systolic anterior motion and mitral regurgitation after septal ablation in obstructive hypertrophic cardiomyopathy. Am J Cardio1,2007,100 : 1691-1695. @@[ 23 ] Lakkis N, Plana JC, Nagueh S, et al. Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. Am J Cardiol,2001,88 :583-586. @@[24] Seggewiss H. Medical therapy versus interventional therapy in hypertrophic obstructive cardiomyopathy. Curr Control Trials Cardiovasc Med,2000,1:115-119. @@[25] Wustmann K, Zbinden S, Windecker S, et al. Is there functional collateral flow during vascular occlusion in angiographically normal coronary arteries? Circulation ,2003,107:2213-2220. @@[26] Holmes DR Jr, Valeti US, Nishimura RA. Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique. Catheter Cardiovasc Interv,2005 ,66 :375-389. @@[27] Sherrid MV. Pathophysiology and treatment of hypertrophic cardiomyopathy. Prog Cardiovasc Dis,2006,49 : 123-151. @@[28] Veselka J, Zemánek D, Tomasov P, et al. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol(1ml) is still effective. Heart Vessels,2009, 24: 27-31. @@[29] Soliman OI,Geleijnse ML, Michels M,et al. Effect of successful alcohol septal ablation on microvascular function in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol,2008,101 : 1321-1327. @@[30] Chang SM, Nagueh SF, Spencer WH 3rd, et al. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol,2003, 42:296-300. @@[31] Veselka J, Procházková S, Duchonová R, et al. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy:lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical outcome. Catheter Cardiovasc Interv, 2004, 63 : 231- 235. @@[32] Cuoco FA, Spencer WH 3rd, Fernandes VL, et al. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardio1,2008,52 : 1718-1723. @@[33]Spirito P,Maron BJ.肥厚型心肌病猝死危险因素分型.中华 心血管病杂志，2009,37:294-297. @@[34] Maron BJ,Spirito P.肥厚型心肌病猝死预防：肥厚型心肌病患 者除颤器置入.中华心血管病杂志，2009,37:297-302. @@[35] Gietzen FH, Leuner CJ, Obergassel L, et al. Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy : feasibility, clinical benefit, and short term results in elderly patients. Heart, 2004,90:638-644. @@[36] Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg, 1996,111:586-594. @@[ 37 ] Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet, 2000, 355:425- 426. @@[38] Lakkis N, Plana JC, Nagueh S, et al. Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. Am J Cardio1,2001,88 :583-586. @@[39] Faber L, Ziemssen P, Seggewiss H. Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. J Am Soc Echocardiogr, 2000, 13: 1074-1079. @@[40] Iacob M, Pinte F, Tintoiu I, et al. Microcoil embolisation for ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy. Kardiol Po1,2004,61:350-355. @@[41 ] Durand E, Mousseaux E, Coste P, et al. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up. Eur Heart J,2008, 29:348-355. @@[42] Buergler JM, Alam S, Spencer W,et al. Initial experience with alcohol septal ablation using a novel magnetic navigation system. J Interv Cardiol, 2007,20:559-663. 2011-08-04 万方数据